Hangzhou Hekang Pharmaceutical Co., Ltd.

It was investigated whether healthy subjects took a single oral administration of Bripipiprazole orally disintegrating tablets (test preparation, specification: 2 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. under fasting and postprandial conditions and a single oral administration of the same drug under the same conditions. Pharmacokinetic characteristics of Brevipiprazole orally disintegrating tablets (reference preparation, trade name: Rexulti® OD Tablets, strength: 2 mg) certified by Otsuka Pharmaceutical Co., Ltd., and evaluation of bioequivalence and safety between the two preparations sex.

This study examined whether healthy subjects took a single oral administration of Bripipiprazole tablets (test preparation, specification: 2 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. under fasting and postprandial conditions, and a single oral administration of Bripipiprazole tablets provided by Hangzhou Hekang Pharmaceutical Co., Ltd. under the same conditions. Pharmacokinetic characteristics of Bripipiprazole tablets (reference preparation, trade name: Rexulti®, strength: 2 mg) licensed by Otsuka Manufacturing Co., Ltd. to evaluate the bioequivalence and safety between the two preparations.

To investigate the pharmacokinetic characteristics of a single oral dose of minocycline hydrochloride capsule [test preparation T, strength: 100 mg (calculated as C23H27N3O7)] provided by Hangzhou Hekang Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions and a single oral dose of minocycline hydrochloride capsule [reference preparation R, trade name: MINOMYCIN®, strength: 100 mg (calculated as C23H27N3O7)] certified by Pfizer Japan Inc. under the same conditions, and to evaluate the bioequivalence and safety of the two preparations.